A 42-year-old man with HIV on antiretroviral therapy (ritonavir-boosted darunavir) develops depression and is prescribed St. John's Wort by a naturopath. His HIV viral load, previously undetectable, rises to 50,000 copies/mL after 3 weeks. He reports perfect medication adherence. Drug levels show subtherapeutic protease inhibitor concentrations despite ritonavir boosting. Evaluate the pharmacokinetic mechanisms and implications of this interaction.
Q2
A 58-year-old woman with metastatic breast cancer is enrolled in a trial of a novel oral chemotherapy agent. Pharmacokinetic studies show the drug has 60% bioavailability, is 95% protein-bound, undergoes extensive CYP3A4 metabolism, and has active metabolites. She develops progressive disease at standard dosing. Genetic testing reveals she is a CYP3A4 ultra-rapid metabolizer. She also has mild hypoalbuminemia (3.0 g/dL). Evaluate the most appropriate pharmacokinetic-guided intervention to optimize therapy.
Q3
A 65-year-old man with hepatocellular carcinoma and Child-Pugh class C cirrhosis develops severe pain. Morphine 5 mg IV provides minimal relief, but he develops profound sedation lasting 8 hours. Repeat dosing causes respiratory depression. Meanwhile, a similar patient with normal liver function tolerates 10 mg IV morphine well with good pain control and normal alertness after 3 hours. Evaluate the pharmacokinetic and pharmacodynamic factors explaining these contrasting responses.
Q4
A 50-year-old man with tuberculosis is started on rifampin. He has been stable on warfarin 5 mg daily for atrial fibrillation with an INR of 2.5. After 10 days of rifampin, his INR drops to 1.2 despite continued warfarin compliance. The warfarin dose is increased to 12 mg daily to achieve therapeutic INR. Three months later, TB treatment is completed and rifampin is discontinued. Analyze what pharmacokinetic changes will occur and predict the management needed.
Q5
A 28-year-old woman with depression is taking fluoxetine 40 mg daily with good symptom control. She develops a fungal infection and is prescribed itraconazole. One week later, she presents with tremor, agitation, confusion, and hyperreflexia. Temperature is 38.9°C (102°F). Analyze the pharmacokinetic mechanism underlying this clinical presentation.
Q6
A 72-year-old man with chronic kidney disease (GFR 25 mL/min/1.73m²) develops acute pain from herpes zoster. He is prescribed gabapentin 300 mg three times daily. After 5 days, he presents with severe drowsiness, confusion, and myoclonus. Serum gabapentin level is markedly elevated. Analyze the pharmacokinetic alterations that led to this presentation.
Q7
A 55-year-old man with newly diagnosed hypertension is started on lisinopril 10 mg daily. His blood pressure is 165/95 mmHg. He has a history of gastroesophageal reflux and takes omeprazole. His BMI is 42 kg/m². After 4 weeks, his blood pressure remains elevated at 160/92 mmHg. Apply your understanding of drug absorption to identify the most likely explanation.
Q8
A 32-year-old pregnant woman at 28 weeks gestation presents with a urinary tract infection. She is prescribed nitrofurantoin. Laboratory values show normal renal function. Two days later, she develops dyspnea and chest tightness. Chest X-ray shows bilateral interstitial infiltrates. Apply pharmacokinetic and pharmacodynamic principles to explain this presentation.
Q9
A 45-year-old woman with severe pneumonia is prescribed gentamicin. Her serum creatinine is 0.9 mg/dL and creatinine clearance is 95 mL/min. Laboratory monitoring shows a trough level of 3.2 μg/mL (therapeutic range: <2 μg/mL). Apply pharmacokinetic principles to determine the most appropriate management.
Q10
A 68-year-old man with atrial fibrillation is started on warfarin therapy. He also takes phenytoin for seizure disorder. After 2 weeks, his INR remains subtherapeutic at 1.3 despite increasing warfarin doses. The patient reports compliance with both medications. Apply your knowledge of pharmacokinetics to explain this drug interaction.
Pharmacokinetics (ADME principles) US Medical PG Practice Questions and MCQs
Question 1: A 42-year-old man with HIV on antiretroviral therapy (ritonavir-boosted darunavir) develops depression and is prescribed St. John's Wort by a naturopath. His HIV viral load, previously undetectable, rises to 50,000 copies/mL after 3 weeks. He reports perfect medication adherence. Drug levels show subtherapeutic protease inhibitor concentrations despite ritonavir boosting. Evaluate the pharmacokinetic mechanisms and implications of this interaction.
A. St. John's Wort induced glucuronidation pathways, creating alternative elimination route
B. St. John's Wort competitively inhibited ritonavir, preventing darunavir boosting
C. St. John's Wort induced P-glycoprotein, increasing intestinal efflux of darunavir
D. St. John's Wort induced CYP3A4, overwhelming ritonavir's inhibitory effect (Correct Answer)
E. St. John's Wort decreased intestinal absorption through altered pH
Explanation: ***St. John's Wort induced CYP3A4, overwhelming ritonavir's inhibitory effect***
- St. John's Wort is a potent inducer of the **CYP3A4 enzyme**, which significantly increases the metabolism of **protease inhibitors** like darunavir.
- While **ritonavir** is used as a booster to inhibit CYP3A4, the induction caused by St. John's Wort is powerful enough to synthesize new enzymes that bypass this inhibition, leading to **subtherapeutic** drug levels and **virologic failure**.
*St. John's Wort induced glucuronidation pathways, creating alternative elimination route*
- While some inducers affect Phase II metabolism, the primary interaction between St. John's Wort and protease inhibitors occurs via **Phase I (CYP450)** pathways.
- **Glucuronidation** is not the major metabolic route for darunavir, so inducing this pathway would not explain the drastic rise in viral load.
*St. John's Wort competitively inhibited ritonavir, preventing darunavir boosting*
- St. John's Wort acts as an **enzyme inducer** rather than a competitive inhibitor of ritonavir.
- Inhibiting ritonavir would potentially reduce its boosting efficacy, but the primary clinical mechanism here is the massive **upregulation** of metabolic enzymes that clear the active drug.
*St. John's Wort induced P-glycoprotein, increasing intestinal efflux of darunavir*
- St. John's Wort does induce **P-glycoprotein (P-gp)**, which can reduce drug absorption; however, this is not the dominant reason for the failure of boosted regimens.
- The **CYP3A4 induction** is the more significant pharmacokinetic driver in this interaction, leading to rapid systemic clearance that exceeds the impact of decreased intestinal absorption.
*St. John's Wort decreased intestinal absorption through altered pH*
- There is no evidence that St. John's Wort significantly alters **gastric or intestinal pH**.
- Absorption issues for protease inhibitors are typically related to food intake or **P-glycoprotein efflux**, rather than pH-dependent solubility changes.
Question 2: A 58-year-old woman with metastatic breast cancer is enrolled in a trial of a novel oral chemotherapy agent. Pharmacokinetic studies show the drug has 60% bioavailability, is 95% protein-bound, undergoes extensive CYP3A4 metabolism, and has active metabolites. She develops progressive disease at standard dosing. Genetic testing reveals she is a CYP3A4 ultra-rapid metabolizer. She also has mild hypoalbuminemia (3.0 g/dL). Evaluate the most appropriate pharmacokinetic-guided intervention to optimize therapy.
A. Measure free drug concentrations and adjust dose based on unbound levels (Correct Answer)
B. Switch to intravenous formulation to bypass first-pass metabolism
C. Transition to more frequent dosing to maintain steady-state concentrations
D. Add a CYP3A4 inhibitor to decrease metabolism and increase parent drug exposure
E. Increase oral dose to compensate for rapid metabolism
Explanation: ***Measure free drug concentrations and adjust dose based on unbound levels***
- Since the drug is **95% protein-bound**, mild **hypoalbuminemia** significantly increases the **unbound (free) fraction**, which is the active component responsible for both efficacy and toxicity. [1]
- Measuring total drug levels would be misleading; evaluating **free drug concentration** ensures safe titration, especially since the patient is an **ultra-rapid metabolizer** and may have high levels of **active metabolites**. [2]
*Switch to intravenous formulation to bypass first-pass metabolism*
- While IV administration bypasses **first-pass metabolism**, the drug's oral bioavailability is already **60%**, and the primary issue is systemic **CYP3A4 ultra-rapid metabolism**, not just gut/hepatic first-pass.
- Changing the route does not address the altered **protein binding** or the risk of toxicity from high concentrations of **active metabolites**.
*Transition to more frequent dosing to maintain steady-state concentrations*
- More frequent dosing helps stabilize fluctuations but does not account for the **increased free fraction** caused by **hypoalbuminemia** or the altered ratio of parent drug to metabolites.
- It fails to address the underlying pharmacogenetic profile which is causing a potentially toxic accumulation of **active metabolites** from **ultra-rapid metabolism**.
*Add a CYP3A4 inhibitor to decrease metabolism and increase parent drug exposure*
- Adding a **CYP3A4 inhibitor** is risky and difficult to titrate, potentially leading to unpredictable levels of both the parent drug and its **active metabolites**.
- This intervention ignores the **pharmacodynamic impact** of the drug's high **protein binding** and the increased risk of toxicity in the setting of low albumin.
*Increase oral dose to compensate for rapid metabolism*
- Increasing the dose in an **ultra-rapid metabolizer** could lead to dangerously high, toxic levels of **active metabolites**, particularly when the **free fraction** is already elevated due to **hypoalbuminemia**.
- Dose escalation without considering **free drug levels** is dangerous for highly protein-bound agents with narrow therapeutic windows. [2]
Question 3: A 65-year-old man with hepatocellular carcinoma and Child-Pugh class C cirrhosis develops severe pain. Morphine 5 mg IV provides minimal relief, but he develops profound sedation lasting 8 hours. Repeat dosing causes respiratory depression. Meanwhile, a similar patient with normal liver function tolerates 10 mg IV morphine well with good pain control and normal alertness after 3 hours. Evaluate the pharmacokinetic and pharmacodynamic factors explaining these contrasting responses.
A. Portosystemic shunting caused immediate higher CNS concentrations
B. Decreased albumin synthesis reduced protein binding, increasing free morphine fraction
C. Enhanced blood-brain barrier permeability in cirrhosis increased CNS sensitivity
D. Impaired hepatic conjugation of morphine plus reduced clearance of active metabolites (Correct Answer)
E. Decreased first-pass metabolism increased oral bioavailability of morphine
Explanation: ***Impaired hepatic conjugation of morphine plus reduced clearance of active metabolites***
- In Child-Pugh class C cirrhosis, **phase II glucuronidation** is significantly impaired, leading to a reduced clearance of morphine and a prolonged half-life.
- The accumulation of **morphine-6-glucuronide (M6G)**, an active and more potent metabolite, occurs due to impaired biliary and renal excretion often seen in advanced liver disease, causing profound **respiratory depression**.
*Portosystemic shunting caused immediate higher CNS concentrations*
- While **portosystemic shunting** bypasses the liver for orally administered drugs, its impact on **intravenous (IV)** administration is negligible as the drug enters the systemic circulation directly.
- Shunting does not explain the **prolonged 8-hour duration** of sedation, which is a function of clearance and metabolism rather than initial distribution.
*Decreased albumin synthesis reduced protein binding, increasing free morphine fraction*
- Morphine has relatively **low protein binding** (about 30%), meaning changes in **albumin levels** have a minimal impact on the free fraction compared to highly protein-bound drugs.
- Increased free fraction might increase immediate intensity but would not account for the **delayed respiratory depression** and prolonged clinical effect seen here.
*Enhanced blood-brain barrier permeability in cirrhosis increased CNS sensitivity*
- Although **hepatic encephalopathy** can increase CNS sensitivity to sedatives, it is a pharmacodynamic factor that doesn't fully explain the specific **pharmacokinetic accumulation** of metabolites.
- This mechanism is less significant than the metabolic failure to clear the **morphine parent compound** and its active metabolites in end-stage liver disease.
*Decreased first-pass metabolism increased oral bioavailability of morphine*
- This factor is irrelevant in this clinical scenario because the patient received the medication via the **intravenous (IV) route**, which bypasses the **first-pass effect** entirely.
- Reduced first-pass metabolism only explains higher plasma levels during **oral administration** in cirrhotic patients with shunting.
Question 4: A 50-year-old man with tuberculosis is started on rifampin. He has been stable on warfarin 5 mg daily for atrial fibrillation with an INR of 2.5. After 10 days of rifampin, his INR drops to 1.2 despite continued warfarin compliance. The warfarin dose is increased to 12 mg daily to achieve therapeutic INR. Three months later, TB treatment is completed and rifampin is discontinued. Analyze what pharmacokinetic changes will occur and predict the management needed.
A. Warfarin dose should be reduced to 8 mg as a compromise between extremes
B. Warfarin metabolism will gradually decrease over 2-3 weeks, requiring dose reduction (Correct Answer)
C. Switch to a direct oral anticoagulant to avoid the interaction completely
D. Immediate return to 5 mg warfarin is safe as enzyme activity normalizes within 24 hours
E. Warfarin requirements will remain at 12 mg due to permanent enzyme changes
Explanation: ***Warfarin metabolism will gradually decrease over 2-3 weeks, requiring dose reduction***
- **Rifampin** is a potent **enzyme inducer** of the **CYP450 system** (specifically CYP2C9), and its effects on enzyme synthesis and degradation are not immediate.
- After stopping rifampin, the induced enzymes must undergo **natural degradation**, which typically takes **2 to 4 weeks** to return to baseline metabolic capacity.
*Warfarin dose should be reduced to 8 mg as a compromise between extremes*
- **Empirical dosing** without close monitoring is dangerous as it may lead to an **under-therapeutic** or **supratherapeutic INR**.
- Dose adjustments must be guided by **frequent INR monitoring** to account for the gradual loss of enzyme induction.
*Switch to a direct oral anticoagulant to avoid the interaction completely*
- While **DOACs** have fewer interactions, this does not address the immediate **pharmacokinetic change** occurring during the transition off rifampin.
- **Rifampin** also induces pathways (like P-glycoprotein) that affect many DOACs, so switching would still require careful timing and monitoring.
*Immediate return to 5 mg warfarin is safe as enzyme activity normalizes within 24 hours*
- Unlike enzyme inhibition, which is rapid, **enzyme induction** involves the synthesis of new proteins and takes a significant amount of time to resolve.
- An immediate drop to 5 mg while enzymes are still highly active would likely cause the **INR to plummet**, increasing the risk of **thromboembolism**.
*Warfarin requirements will remain at 12 mg due to permanent enzyme changes*
- Enzyme induction is a **reversible process** and does not lead to permanent changes in the genetic expression or structure of **CYP450 enzymes**.
- Maintaining the 12 mg dose after induction has resolved would lead to **excessive anticoagulation** and a high risk of **major bleeding**.
Question 5: A 28-year-old woman with depression is taking fluoxetine 40 mg daily with good symptom control. She develops a fungal infection and is prescribed itraconazole. One week later, she presents with tremor, agitation, confusion, and hyperreflexia. Temperature is 38.9°C (102°F). Analyze the pharmacokinetic mechanism underlying this clinical presentation.
A. Itraconazole inhibited CYP3A4, preventing fluoxetine elimination (Correct Answer)
B. Itraconazole inhibited CYP2D6, decreasing fluoxetine metabolism
C. Itraconazole enhanced P-glycoprotein, increasing CNS drug penetration
D. Itraconazole induced CYP3A4, increasing norfluoxetine formation
E. Itraconazole displaced fluoxetine from plasma proteins, increasing free drug
Explanation: ***Itraconazole inhibited CYP3A4, preventing fluoxetine elimination***
- **Itraconazole** is a potent inhibitor of the **CYP3A4** enzyme system, which plays a critical role in the metabolic clearance of **Fluoxetine**.
- Inhibition of this pathway leads to toxic accumulation of serotonin, manifesting as **Serotonin Syndrome** characterized by hyperreflexia, agitation, and hyperthermia.
*Itraconazole inhibited CYP2D6, decreasing fluoxetine metabolism*
- While **Fluoxetine** itself is a known inhibitor of **CYP2D6**, **Itraconazole**'s primary inhibitory effect is on the **CYP3A4** isoenzyme.
- **CYP2D6** inhibition is not the characteristic pharmacokinetic profile of azole antifungals like **Itraconazole**.
*Itraconazole enhanced P-glycoprotein, increasing CNS drug penetration*
- **Itraconazole** typically acts as an inhibitor, not an enhancer, of **P-glycoprotein** (P-gp) efflux pumps.
- The systemic toxicity and **Serotonin Syndrome** seen here are driven by metabolic inhibition in the liver rather than altered **blood-brain barrier** transport.
*Itraconazole induced CYP3A4, increasing norfluoxetine formation*
- **Itraconazole** is a potent enzymatic **inhibitor**, not an inducer; an inducer would decrease drug levels rather than causing toxicity.
- Increased **CYP3A4** activity would accelerate the clearance of **Fluoxetine**, which contradicts the clinical presentation of drug toxicity.
*Itraconazole displaced fluoxetine from plasma proteins, increasing free drug*
- While many drugs compete for **albumin** binding, clinical toxicity from **Fluoxetine** is rarely attributed to **plasma protein displacement**.
- The profound elevation of drug levels leading to **Serotonin Syndrome** in this context is almost always due to **hepatic enzyme inhibition**.
Question 6: A 72-year-old man with chronic kidney disease (GFR 25 mL/min/1.73m²) develops acute pain from herpes zoster. He is prescribed gabapentin 300 mg three times daily. After 5 days, he presents with severe drowsiness, confusion, and myoclonus. Serum gabapentin level is markedly elevated. Analyze the pharmacokinetic alterations that led to this presentation.
A. Blood-brain barrier permeability increased due to uremia
B. Impaired renal excretion caused drug accumulation beyond steady-state predictions (Correct Answer)
C. Drug-drug interaction with endogenous uremic toxins inhibited transporters
D. Hepatic metabolism was saturated, leading to zero-order kinetics
E. Decreased protein binding increased free drug concentration
Explanation: ***Impaired renal excretion caused drug accumulation beyond steady-state predictions***
- **Gabapentin** is eliminated almost exclusively by the **kidneys** as an unchanged drug, making its clearance directly proportional to the **glomerular filtration rate (GFR)**.
- In patients with **Chronic Kidney Disease (CKD)**, the half-life is significantly prolonged, leading to **toxic accumulation** and neurotoxicity symptoms like **myoclonus** and confusion if the dose is not reduced.
*Blood-brain barrier permeability increased due to uremia*
- While **uremia** can alter the **blood-brain barrier (BBB)**, the primary cause of toxicity in this case is the physical accumulation of the drug in the blood due to poor clearance.
- Broad CNS symptoms in this patient are specifically correlated with the **markedly elevated serum gabapentin levels**, not just sensitivity changes.
*Drug-drug interaction with endogenous uremic toxins inhibited transporters*
- Though uremic toxins can interfere with some transporters, the high levels of gabapentin are primarily due to the failure of **passive filtration** and active secretion mechanisms in a diseased kidney.
- This mechanism is less clinically relevant than the fundamental reduction in **renal clearance** (ClR) seen in Stage 4 CKD.
*Hepatic metabolism was saturated, leading to zero-order kinetics*
- **Gabapentin** does not undergo **hepatic metabolism** or bind to plasma proteins; therefore, saturation of metabolic enzymes is not possible.
- It maintains **first-order kinetics** relative to renal function, but the elimination rate constant is drastically lowered in renal failure.
*Decreased protein binding increased free drug concentration*
- Gabapentin exhibits **negligible protein binding** (<3%), so changes in albumin or uremic displacement do not affect its pharmacokinetics.
- Toxicity is driven by the total **plasma concentration** rising due to impaired excretion, rather than an increase in the free fraction.
Question 7: A 55-year-old man with newly diagnosed hypertension is started on lisinopril 10 mg daily. His blood pressure is 165/95 mmHg. He has a history of gastroesophageal reflux and takes omeprazole. His BMI is 42 kg/m². After 4 weeks, his blood pressure remains elevated at 160/92 mmHg. Apply your understanding of drug absorption to identify the most likely explanation.
A. The patient requires more time to reach steady-state concentrations
B. Increased volume of distribution due to obesity requires higher doses
C. Lisinopril absorption is adequate; the dose is simply insufficient (Correct Answer)
D. First-pass metabolism is enhanced in obese patients
E. Omeprazole decreases gastric acidity, reducing lisinopril absorption
Explanation: ***Lisinopril absorption is adequate; the dose is simply insufficient***
- **Lisinopril** is a **hydrophilic** drug with predictable absorption (25-30%) and its bioavailability is generally **unaffected by food** or gastric pH.
- Given the patient's baseline blood pressure and **BMI**, a starting dose of 10 mg is often inadequate to reach therapeutic targets, requiring **dose titration**.
*The patient requires more time to reach steady-state concentrations*
- **Steady-state** is typically achieved after **4-5 half-lives**; since lisinopril has a half-life of 12 hours, steady-state is reached within 3 days.
- After **4 weeks**, the drug levels have long since stabilized, so the lack of response is due to dose potency, not timing.
*Increased volume of distribution due to obesity requires higher doses*
- **Volume of distribution** changes in obesity primarily affect **lipophilic drugs** that sequester in adipose tissue.
- **Lisinopril** is **water-soluble** (hydrophilic) and distributes mainly to extracellular fluid, making this pharmacokinetic explanation less relevant than dosing requirements.
*First-pass metabolism is enhanced in obese patients*
- **Lisinopril** is unique among most ACE inhibitors as it is **not a prodrug** and does not undergo **hepatic metabolism**.
- It is excreted **unchanged** by the kidneys, so changes in first-pass metabolism do not impact its serum concentration.
*Omeprazole decreases gastric acidity, reducing lisinopril absorption*
- The absorption of **lisinopril** is not dependent on **gastric pH**, meaning the use of **proton pump inhibitors** like omeprazole does not interfere with its uptake.
- Factors like **gastrointestinal transit time** are more significant for absorption than the acidity changes caused by GERD medications for this specific drug.
Question 8: A 32-year-old pregnant woman at 28 weeks gestation presents with a urinary tract infection. She is prescribed nitrofurantoin. Laboratory values show normal renal function. Two days later, she develops dyspnea and chest tightness. Chest X-ray shows bilateral interstitial infiltrates. Apply pharmacokinetic and pharmacodynamic principles to explain this presentation.
A. Decreased hepatic metabolism resulted in drug accumulation and toxicity
B. Enhanced renal clearance caused metabolite accumulation in lung tissue
C. Placental transfer of drug caused fetal distress and maternal symptoms
D. Drug-induced hypersensitivity reaction independent of plasma concentration (Correct Answer)
E. Increased volume of distribution in pregnancy led to subtherapeutic drug levels
Explanation: ***Drug-induced hypersensitivity reaction independent of plasma concentration***
- This patient is experiencing **acute nitrofurantoin-induced pulmonary toxicity**, which is an **idiosyncratic hypersensitivity reaction** rather than dose-dependent toxicity.
- The sudden onset of **dyspnea** and **bilateral interstitial infiltrates** within days of starting the drug is characteristic of an **immunologic response** to the medication.
*Decreased hepatic metabolism resulted in drug accumulation and toxicity*
- Nitrofurantoin is primarily eliminated via **renal excretion**, and its pulmonary toxicity is not typically linked to hepatic metabolic dysfunction.
- This reaction is **hypersensitivity-based** and occurs even with standard therapeutic dosing and normal drug metabolism.
*Enhanced renal clearance caused metabolite accumulation in lung tissue*
- **Enhanced renal clearance** would decrease plasma levels, making dose-dependent toxicity less likely, not more.
- There is no clinical evidence that highly cleared metabolites specifically sequester in **lung tissue** to cause this acute presentation.
*Placental transfer of drug caused fetal distress and maternal symptoms*
- While nitrofurantoin does cross the **placenta**, it is generally considered safe in the second trimester and does not manifest as maternal **pulmonary infiltrates** via fetal distress.
- The symptoms described are classic for **maternal drug-induced pneumonitis**, a known rare complication of nitrofurantoin therapy.
*Increased volume of distribution in pregnancy led to subtherapeutic drug levels*
- An increased **volume of distribution** would result in **subtherapeutic levels**, which would explain a failure to treat the infection, but not the development of toxicity.
- Drug-induced **interstitial lung disease** is an adverse reaction that is typically independent of the drug achieving specific therapeutic or subtherapeutic serum concentrations.
Question 9: A 45-year-old woman with severe pneumonia is prescribed gentamicin. Her serum creatinine is 0.9 mg/dL and creatinine clearance is 95 mL/min. Laboratory monitoring shows a trough level of 3.2 μg/mL (therapeutic range: <2 μg/mL). Apply pharmacokinetic principles to determine the most appropriate management.
A. Decrease the dose while maintaining the same dosing interval
B. Add a second antibiotic and discontinue gentamicin
C. Continue current regimen as levels are within acceptable range
D. Switch to continuous infusion of gentamicin
E. Increase the dosing interval while maintaining the same dose (Correct Answer)
Explanation: ***Increase the dosing interval while maintaining the same dose***
- **Gentamicin** exhibits **concentration-dependent killing**, meaning efficacy is driven by peak concentration (Cmax); maintaining the dose ensures this peak remains effective.
- An elevated **trough level** (3.2 μg/mL) suggests drug accumulation; **increasing the dosing interval** allows more time for renal clearance to lower the trough and reduce **nephrotoxicity** and **ototoxicity** risk.
*Decrease the dose while maintaining the same dosing interval*
- Reducing the dose would lower the **peak concentration**, which may compromise the drug's **bactericidal efficacy** in concentration-dependent antibiotics.
- While it might lower the trough, it does not address the fundamental need for a longer washout period to utilize the **post-antibiotic effect**.
*Add a second antibiotic and discontinue gentamicin*
- Discontinuing a drug based on an adjustable pharmacokinetic parameter is premature if the patient is responding and renal function is **stable**.
- This approach is generally reserved for cases of documented **gentamicin resistance** or signs of overt **acute kidney injury** (AKI).
*Continue current regimen as levels are within acceptable range*
- The therapeutic range for gentamicin trough is typically **<2 μg/mL**; a level of 3.2 μg/mL is significantly elevated and increases the risk of toxicity.
- Ignoring an elevated trough level in **aminoglycoside** therapy is clinically unsafe and can lead to irreversible **vestibular or cochlear damage**.
*Switch to continuous infusion of gentamicin*
- Aminoglycosides are rarely administered via **continuous infusion** because they require high peak concentrations and a drug-free interval to minimize uptake in the **renal cortex**.
- Continuous exposure at the cell surface increases the risk of **toxicity** compared to traditional or extended-interval dosing regimens.
Question 10: A 68-year-old man with atrial fibrillation is started on warfarin therapy. He also takes phenytoin for seizure disorder. After 2 weeks, his INR remains subtherapeutic at 1.3 despite increasing warfarin doses. The patient reports compliance with both medications. Apply your knowledge of pharmacokinetics to explain this drug interaction.
A. Phenytoin decreases warfarin absorption in the gastrointestinal tract
C. Phenytoin increases renal clearance of warfarin metabolites
D. Phenytoin competes with warfarin for plasma protein binding sites
E. Phenytoin inhibits cytochrome P450 enzymes, decreasing warfarin metabolism
Explanation: ***Phenytoin induces cytochrome P450 enzymes, increasing warfarin metabolism***
- **Phenytoin** is a potent inducer of hepatic **CYP450 enzymes** (specifically **CYP2C9** and **CYP3A4**), which leads to the accelerated breakdown of warfarin.
- Increased **metabolism** lowers the plasma concentration of warfarin, resulting in a **subtherapeutic INR** and a reduced anticoagulant effect.
*Phenytoin decreases warfarin absorption in the gastrointestinal tract*
- Warfarin is rapidly and almost completely absorbed in the **gastrointestinal tract**; phenytoin does not clinically affect this process.
- Interactions involving **absorption** are typical of drugs like **cholestyramine**, not anticonvulsants.
*Phenytoin increases renal clearance of warfarin metabolites*
- While **renal clearance** eliminates metabolites, the primary rate-limiting step for warfarin's effect is its **metabolic inactivation** in the liver.
- Altering the clearance of already **inactive metabolites** would not significantly change the therapeutic **INR** value.
*Phenytoin competes with warfarin for plasma protein binding sites*
- Although both drugs are highly **protein-bound**, displacement would initially **increase** the free fraction of warfarin, potentially raising the INR temporarily.
- In this scenario, the long-term effect of **CYP induction** outweighs any transient protein displacement, leading to the observed **subtherapeutic** levels.
*Phenytoin inhibits cytochrome P450 enzymes, decreasing warfarin metabolism*
- **Enzyme inhibition** would lead to toxic levels of warfarin and an **elevated INR**, increasing the risk of bleeding.
- Phenytoin is a well-known **enzyme inducer**, whereas drugs like **amiodarone** or **fluconazole** act as hepatic inhibitors.
